期刊文献+
共找到794篇文章
< 1 2 40 >
每页显示 20 50 100
Study on the Effects of National Volume-Based Procurement of Chemical Drugs on Chinese Patent Medicines:Lipid-Lowering Drugs as an Example
1
作者 Zhao Yang Xiao Han +5 位作者 Pei Liang Xiaoting Zhao Qiyun Zhu Hui Ye Chao Yang Bin Jiang 《Health Care Science》 2025年第1期14-24,共11页
Background:Atherosclerotic cardiovascular disease remains the leading cause of death worldwide.This study aims to explore the impact of national volume-based procurement(NVBP)on Chinese patent medicines and provide ev... Background:Atherosclerotic cardiovascular disease remains the leading cause of death worldwide.This study aims to explore the impact of national volume-based procurement(NVBP)on Chinese patent medicines and provide evidence for improving policies and promoting rational drug use.Methods:The study was based on data from the China National Health Insurance Agency that spanned January 2019 to December 2020.Descriptive analysis was conducted using volume and expenditure as variables.Interrupted time series analysis was applied to further analyze Chinese patent medicines.Results:The unit prices of atorvastatin and rosuvastatin decreased by 25%-96%,whereas the prices of Zhibitai and Xuezhikang fluctuated slightly.The affordability is measured as the monthly expenditure on treatment divided by the daily wage.After policy implementation,the affordability of atorvastatin and rosuvastatin improved from 0.242 to 0.014 and from 0.247 to 0.019,respectively.The defined daily doses(DDDs)for atorvastatin and rosuvastatin also increased,whereas total expenditures decreased in hospitals of all levels.Both at the national level and at all levels of hospital,the policy had no significant impact on expenditures for Zhibitai and Xuezhikang and their defined daily doses.Conclusions:The NVBP saved costs in the short term by incorporating high-quality,widely used lipid-lowering drugs.Notably,the policy impacted lipid-lowering chemical drugs,whereas Chinese patent medicines remained largely unaffected.Doctors'use of Chinese patent medicines did not decline,highlighting the clinical specificity of these medicines. 展开更多
关键词 Chinese patent medicine health policy lipid-lowering drugs national volume-based procurement
暂未订购
Quantitative Analysis of the Policy of Centralized Drug Procurement Based on PMC Index Model
2
作者 Duan Xiaoxiang Wang Shuling 《Asian Journal of Social Pharmacy》 2025年第3期222-235,共14页
Objective To quantitatively analyze the policy of centralized drug procurement centralized drug procurement in order to provide reference for the subsequent policy formulation and improvement.Methods Text mining metho... Objective To quantitatively analyze the policy of centralized drug procurement centralized drug procurement in order to provide reference for the subsequent policy formulation and improvement.Methods Text mining method was used to process 15 centralized drugs procurement policies issued at the national level during 2015-2022,and a PMC index evaluation model of centralized drug procurement policies was established.Then,15 centralized drug procurement policies were quantitatively analyzed from the overall and comparative perspective through an evaluation model.Results and Conclusion The average PMC index of 15 centralized drug procurement policies was 6.95,which was acceptable on the whole.Among them,eight were excellent and seven were acceptable.As to the first-order variables,the centralized drugs procurement policy still lacks incentives and constraints.The comparative results show that there are differences in the content and structure of policies,but they are strongly related to each other.Chinese centralized drug procurement policy has been basically formed,which is closely related to medical insurance and medical policies.However,it is still necessary to pay attention to the structure of the policy to ensure the elaboration of the policy content. 展开更多
关键词 centralized drug procurement PMC index POLICY quantitative analysis
暂未订购
Construction of Evaluation Index System for the Policy Effect of Centralized Drug Procurement
3
作者 Huang Jiaxin Raela·Abduhilil +2 位作者 Hu Ping Liu Xinying Sun Lihua 《Asian Journal of Social Pharmacy》 2025年第4期313-324,共12页
Objective To construct an index system for evaluating the policy effect of centralized drug procurement,and to provide reference for comprehensively and systematically evaluating the policy of centralized drug procure... Objective To construct an index system for evaluating the policy effect of centralized drug procurement,and to provide reference for comprehensively and systematically evaluating the policy of centralized drug procurement.Methods Through combing the policies and literature research,the focus and expected goal of China’s centralized drug procurement policy were clarified.On the basis of policy concerns,combined with some theories and the implementation of drug centralized procurement policy,a primary evaluation index system was constructed.The index system was determined by expert consultation,and the weight of each index was calculated by analytic hierarchy process.Results and Conclusion The questionnaire recovery rates of the two rounds of expert consultation were 88.23%and 100%,the coefficients of authority of experts were 0.86 and 0.80,and the expert coordination coefficients were 0.338 and 0.294,respectively.Finally,the evaluation index system for the policy of centralized drug procurement was established,which included 4 first-level indicators,10 second-level indicators and 23 third-level indicators.The evaluation index system constructed in this paper can not only make up for the deficiency of systematic evaluation of the policy effect of the current centralized drug procurement,but also provide reference for further improving this policy. 展开更多
关键词 centralized drug procurement STAKEHOLDER policy evaluation
暂未订购
The Management Practice and Reflection of Centralized Drug Procurement in Hospitals
4
作者 Yuchen Li 《Proceedings of Business and Economic Studies》 2025年第3期54-59,共6页
The centralized procurement of drugs in the medical system is a key link,which not only affects the economic effect of institutions,but also relates to the medical quality and patient safety.In the current era,central... The centralized procurement of drugs in the medical system is a key link,which not only affects the economic effect of institutions,but also relates to the medical quality and patient safety.In the current era,centralized drug procurement in hospitals can meet the needs of most patients;however,the specific steps of the work still need to be optimized.Starting from the level of hospital drug centralized procurement work,this paper discusses the policy background,analyzes the practice of drug centralized procurement in tertiary hospitals,and provides specific work management suggestions,aiming to improve work efficiency and serve as a reference for optimizing subsequent hospital drug centralized procurement work. 展开更多
关键词 Hospital drugs centralized procurement work Management practice Suggestions
暂未订购
Application Value of PDCA in Hospital Centralized Procurement Quality Management
5
作者 WU Guixin 《外文科技期刊数据库(文摘版)医药卫生》 2021年第7期047-049,共5页
Objective: to analyze the application value of PDCA (Plan-do-check-act) management model in hospital centralized procurement quality management. Methods: from January 2019 to June 2020, our hospital began to apply PDC... Objective: to analyze the application value of PDCA (Plan-do-check-act) management model in hospital centralized procurement quality management. Methods: from January 2019 to June 2020, our hospital began to apply PDCA management model to the quality management of hospital centralized procurement. By using the basic process of planning-implementation-inspection-improvement, and establishing and further optimizing the procurement organization at the organizational level, further formulating and revising the procurement system for the procurement system, centralized procurement and organizing bidding at the operational level. Results: through the application of PDCA management mode, the procurement process can be optimized and necessary optimization can be made for the procurement process, with a significant overall effect. Through the application of PDCA, the procurement task was completed to 100%, and the procurement cost was saved by more than 11.70%, while the quality and satisfaction of the hospital demand department to the purchased products reached 99.67%. Conclusion: the application of PDCA management model in hospital centralized procurement is particularly critical to improve the quality of procurement, which can achieve the objectives of saving procurement costs, improving the quality of purchased products and procurement satisfaction. 展开更多
关键词 PDCA management model centralized procurement procurement costs procurement quality procurement
暂未订购
Analysis on the Mode of Centralized Material Procurement of Group City Gas Enterprises
6
作者 CAO Qili 《外文科技期刊数据库(文摘版)经济管理》 2021年第11期121-124,共6页
With the continuous development of the domestic natural gas market and the increasing trend of group operation of city gas enterprises, each large and medium-sized gas group enterprise cannot achieve cost reduction, e... With the continuous development of the domestic natural gas market and the increasing trend of group operation of city gas enterprises, each large and medium-sized gas group enterprise cannot achieve cost reduction, efficiency improvement and market competitiveness without an efficient centralized procurement system. However, the centralized procurement mode of gas enterprises has gradually deepened from the simple bundle procurement to the standardized and scientific centralized procurement supply chain mode. Based on the summary and analysis of the material centralized purchase mode of a medium-sized city gas group in recent ten years, this paper further explores the idea of the construction of centralized purchase supply chain. 展开更多
关键词 city gas group centralized procurement of materials centralized procurement supply chain
原文传递
Strategic Research on Pharmaceutical Enterprises’ Participation in National Drug Centralized Procurement
7
作者 Yang Dianzheng Xu Wenxiu +1 位作者 Qi Yun Yang Yue 《Asian Journal of Social Pharmacy》 2022年第1期15-22,共8页
Objective To study the influence of national drug centralized procurement policy on pharmaceutical enterprises manufacturing generic drugs and original drugs,so as to provide a reference for them to make different str... Objective To study the influence of national drug centralized procurement policy on pharmaceutical enterprises manufacturing generic drugs and original drugs,so as to provide a reference for them to make different strategic choices.Methods Through the literature research on the related policies and the bidding data,the national drug centralized policies were studied systematically.Combined with the bid-winning price and price reduction range of the winning enterprises in the three rounds of centralized procurement,their difficulties,strategic choices and the winning factors were investigated.Besides,a model was established to clarify the optimal price of enterprises in the process of drug procurement.Results and Conclusion The strategic choices of enterprises in participating national drug centralized procurement are influenced by many factors such as the market share of the original varieties,active pharmaceutical ingredients(APIs)and cost.Therefore,corresponding strategies should be formulated according to the characteristics and interests of enterprises. 展开更多
关键词 drug centralized procurement pharmaceutical enterprises GAME STRATEGY
暂未订购
The Establishment of Management Mode of Centralized Procurement
8
作者 CHEN Keren DU Ping 《外文科技期刊数据库(文摘版)经济管理》 2021年第8期052-055,共6页
In order to implement the relevant provisions of the State-owned Assets Supervision and Administration Commission on the benchmarking of procurement management, improve the effectiveness of procurement, reduce procure... In order to implement the relevant provisions of the State-owned Assets Supervision and Administration Commission on the benchmarking of procurement management, improve the effectiveness of procurement, reduce procurement costs and control the risks of integrity in procurement, the Group Company will step by step promote centralized procurement, build a centralized procurement management system for the Group Company, build an information system for centralized procurement management, give full play to the advantages of overall procurement, strengthen implementation supervision, form a sustainable long-term mechanism for centralized procurement, promote the overall improvement of the procurement management capabilities of units at all levels of the Group Company, and organize member units and subordinate units to implement centralized and unified external procurement of materials, projects and services included in the centralized procurement catalog. The Company adheres to the principle of "overall management and control, platform operation, supervision and balance, intensive and efficient", implements the requirements of the Group Company from the aspects of organizational structure and functions, contract signing methods, business processes, data statistics and analysis, supplier management, inspection and supervision, assessment and evaluation, and establishes a centralized procurement management model. The unit and its subordinate units will hand over the items in the centralized procurement catalog to the centralized procurement platform for unified negotiation and procurement, which will bring into play the economies of scale, save procurement costs, simplify procurement process, reduce procurement risks and improve procurement efficiency. 展开更多
关键词 centralized procurement management system signing of contracts supplier management
原文传递
Suggestions on Foreign Pharmaceutical Enterprises Dealing with China’s Drug Centralized Procurement - Taking the First Batch of Implementation Results as an Example
9
作者 Li Yunlong Ning Bowen Yuan Hongmei 《Asian Journal of Social Pharmacy》 2022年第1期23-33,共11页
Objective To analyze the impact of the first batch of centralized drug procurement on foreign pharmaceutical enterprises since the national centralized drug procurement policy has brought great impact on pharmaceutica... Objective To analyze the impact of the first batch of centralized drug procurement on foreign pharmaceutical enterprises since the national centralized drug procurement policy has brought great impact on pharmaceutical market,and put forward some suggestions on their marketing transformation in China.Methods Firstly,the documents of the drug centralized procurement were studied,and then the sales figures before and after the implementation of the policy were retrieved from MiNET.At the same time,the relevant business adjustment information of foreign pharmaceutical enterprises was collected for analysis.Results and Conclusion The sales of related products of foreign pharmaceutical enterprises have dropped sharply,so they have stripped off these products and reduced their staff.It is suggested that foreign pharmaceutical enterprises should adjust the structure of sales team,strengthen the layout of the market in the county,and accelerate the introduction of innovative drugs to cope with centralized drug procurement. 展开更多
关键词 centralized procurement foreign pharmaceutical enterprise drug price MARKETING REFORM
暂未订购
Analysis on the Application of Information Technology in the Centralized Procurement Management of Modern Enterprise Materials
10
作者 MENGXiangsheng 《外文科技期刊数据库(文摘版)经济管理》 2022年第6期017-020,共4页
In the process of production and operation of modern enterprises, material procurement management is a necessary basic link in production. However, due to the limitations of management methods and technical means, inf... In the process of production and operation of modern enterprises, material procurement management is a necessary basic link in production. However, due to the limitations of management methods and technical means, information technology has certain deficiencies in the centralized material procurement management of modern enterprises, which has a relatively intuitive impact on the centralized material procurement management. Therefore, this paper takes the practical application of information technology in the centralized procurement management of modern enterprise materials as the breakthrough point, and fully analyzes the significance of information technology in the production, operation and management of modern enterprises. At the same time, it makes judgment and observation on the practical problems existing in the application of information technology in the centralized procurement management of materials as the main research content, so as to put forward targeted countermeasures and management methods, so as to ensure the orderly development of the centralized procurement management of materials in modern enterprises and lay a solid foundation for the stable development of subsequent enterprises. 展开更多
关键词 information technology modern enterprise centralized procurement management of materials
原文传递
仿制与原研利奈唑胺葡萄糖注射液临床疗效比较
11
作者 王之舟 王可 +6 位作者 邢晓璇 花一鸣 张晓彤 李晓曦 冯英楠 董宪喆 张兰 《中国抗生素杂志》 北大核心 2026年第2期227-234,共8页
目的比较集采中选仿制与原研利奈唑胺葡萄糖注射液治疗细菌感染的临床疗效,为国家组织集采中选利奈唑胺葡萄糖注射液的临床使用及效果评价提供真实世界证据。方法回顾性收集首都医科大学宣武医院在2019年1月—2023年6月期间使用集采中... 目的比较集采中选仿制与原研利奈唑胺葡萄糖注射液治疗细菌感染的临床疗效,为国家组织集采中选利奈唑胺葡萄糖注射液的临床使用及效果评价提供真实世界证据。方法回顾性收集首都医科大学宣武医院在2019年1月—2023年6月期间使用集采中选仿制或原研利奈唑胺葡萄糖注射液治疗成人细菌感染患者的诊疗资料。采用1:1倾向性评分匹配法平衡了组间人口统计学特征、合并症、感染类型及其严重程度、合并用药和治疗等关键指标。对集采中选仿制组和原研组患者的住院期间生存情况、28 d感染治疗成功率、3 d体温恢复率、换药率、住院时间以及治疗后体温和实验室检查指标的变化进行了比较分析。结果共纳入485例使用集采中选仿制或原研利奈唑胺葡萄糖注射液的患者,1:1匹配后每组各155例。集采中选仿制组较原研组住院死亡风险比(HR0.848,95%CI:0.51~1.40,P=0.530)及住院全因死亡率(18.7%vs 21.3%,P=0.670)均未达到统计显著性。在28 d感染治疗成功率(72.9%vs 63.9%)、3 d体温恢复率(88.2%vs 82.9%)、换药率(8.4%vs 12.9%)以及平均住院时间(27.76 d vs 29.61 d)方面,组间差异均无统计显著性(P>0.05)。利奈唑胺葡萄糖注射液治疗后体温和实验室检查值分布相似,组间差异不具有临床意义。结论集采中选仿制利奈唑胺葡萄糖注射液与原研药在治疗成人细菌感染方面临床疗效相当。 展开更多
关键词 国家集中带量采购 利奈唑胺 仿制药 原研药 疗效 抗菌药物
暂未订购
集采与原研布地奈德联合特布他林辅助治疗儿童支气管肺炎有效性、安全性和经济性评价
12
作者 汪江涛 蒋慧莲 +3 位作者 叶鸣 方佳 赵磊 丁伯平 《中国药业》 2026年第4期132-135,共4页
目的评价集中带量采购(以下简称集采)与原研吸入用布地奈德混悬液(以下简称布地奈德)联合硫酸特布他林雾化吸入用溶液(以下简称特布他林)辅助治疗儿童支气管肺炎的有效性、安全性和经济性。方法选取医院2023年1月至2024年6月收治的儿童... 目的评价集中带量采购(以下简称集采)与原研吸入用布地奈德混悬液(以下简称布地奈德)联合硫酸特布他林雾化吸入用溶液(以下简称特布他林)辅助治疗儿童支气管肺炎的有效性、安全性和经济性。方法选取医院2023年1月至2024年6月收治的儿童支气管肺炎患儿160例,根据辅助药物来源的不同,分为集采组和原研组,各80例。两组患儿均予常规治疗和布地奈德联合特布他林雾化吸入辅助治疗,比较两组患儿的病情改善时间(含体温恢复时间、咳嗽消失时间、气喘消失时间、肺部罗音消失时间)、住院时间、临床疗效、药品不良反应(ADR)发生情况,并使用成本-效果比(C/E)评价药物经济性。结果有效性方面,集采组与原研组总有效率相当(96.25%比97.50%,P>0.05),且两组患儿病情改善时间和住院时间比较均无显著差异(P>0.05);安全性方面,集采组与原研组ADR发生率相当(8.75%比7.50%,P>0.05);经济性方面,集采组药物C/E值为0.67±0.06,显著低于原研组的2.52±0.24,且成本波动±10%时,集采组药物C/E值仍显著低于原研组(P<0.001)。结论集采和原研布地奈德联合特布他林雾化吸入辅助治疗儿童支气管肺炎的有效性和安全性相当,但集采药品经济性更好。 展开更多
关键词 药品集中带量采购 布地奈德 特布他林 支气管肺炎 患儿 综合评价
暂未订购
口腔种植系统集中带量采购实施效果分析及建议
13
作者 高燕华 杜广智 +2 位作者 赵莹颖 吴春旭 范宝林 《医院管理论坛》 2026年第1期38-41,共4页
分析某三级专科医院的口腔种植系统集中带量采购的实施情况,通过总结取得的效果及执行中出现的问题,提出思考及建议。旨在建立医院长效管理机制,构建科学管理体系,促进集中带量采购医用耗材的合理使用,从而达到持续加强医用耗材集中带... 分析某三级专科医院的口腔种植系统集中带量采购的实施情况,通过总结取得的效果及执行中出现的问题,提出思考及建议。旨在建立医院长效管理机制,构建科学管理体系,促进集中带量采购医用耗材的合理使用,从而达到持续加强医用耗材集中带量采购管理的目的,为迎接其他医用耗材的集中带量采购工作提供有益借鉴,推动医院高质量发展。 展开更多
关键词 口腔种植系统 集中带量采购 医用耗材价格
暂未订购
集采背景下中药饮片浙贝母的质量分级探索性研究
14
作者 刘立权 王鑫昱 +2 位作者 吕兰 王姝静 吴敏 《医学研究前沿》 2026年第1期129-132,共4页
目的基于外在形态和内在质量建立浙贝母饮片的质量分级标准。方法对采集的浙贝母饮片20批样品,运用水分、醇浸出物、水浸出物、有效成分含量、饮片直径5个主要的质量指标开展描叙统计分析、相关性分析以及主成分分析等工作探索合理可行... 目的基于外在形态和内在质量建立浙贝母饮片的质量分级标准。方法对采集的浙贝母饮片20批样品,运用水分、醇浸出物、水浸出物、有效成分含量、饮片直径5个主要的质量指标开展描叙统计分析、相关性分析以及主成分分析等工作探索合理可行的质量分级方法。结果不同批次浙贝母饮片的质量差异很大,醇浸出物的含量在19.50%~45.30%之间,水浸出物含量在25.10%~36.50%之间,两者间有很强的负相关关系(r=-0.94);饮片直径与有效成分含量呈显著负相关(r=-0.57,P<0.05);主成分分析显示,水浸出物和有效成分含量是影响浙贝母饮片质量的两大主因子,二者决定着浙贝母饮片整体质量。结论制定集采场景下浙贝母的质量三级分级标准。 展开更多
关键词 药品集中采购 浙贝母 中药饮片 质量分级 浸出物
暂未订购
某妇幼专科医院国家集采抗菌药物使用情况分析
15
作者 张杜娟 李国辉 李国庆 《中国药业》 2026年第4期41-45,共5页
目的分析国家组织药品集中带量采购(以下简称集采)政策对某妇幼专科医院抗菌药物使用的影响。方法统计医院抗菌药物集采前后1年的药品名称、规格、生产企业、价格、用量及使用金额等基本信息,分析其变化,并计算以上药物的用药频度(DDDs... 目的分析国家组织药品集中带量采购(以下简称集采)政策对某妇幼专科医院抗菌药物使用的影响。方法统计医院抗菌药物集采前后1年的药品名称、规格、生产企业、价格、用量及使用金额等基本信息,分析其变化,并计算以上药物的用药频度(DDDs)、限定日费用(DDC)及实际节省费用。结果共纳入6批(第二、三、四、五、七、八批)23种国家集采抗菌药物。与集采前比较,集采后20个品种价格下降,以奥硝唑注射剂降幅最大(96.40%),氨曲南注射剂降幅最小(11.71%),3个品种(头孢唑林注射剂、头孢呋辛注射剂和氟康唑注射剂)价格上涨(>500%);17个品种集采后药物用量及DDDs下降,以氨曲南注射剂降幅最大(均为100.00%),6个品种升高,以哌拉西林他唑巴坦注射剂升幅最大(154.74%);除头孢唑林注射剂、头孢呋辛注射剂、氟康唑注射剂升高外,其余品种的使用金额及DDC均下降;实际节省费用以哌拉西林他唑巴坦注射剂最多(2398077.38元),所有集采品种共计节省费用6925021.24元。结论集采后,该院大部分抗菌药物用量和DDDs,以及使用金额和DDC均不同程度降低,有效减轻了患者和社会的经济负担。 展开更多
关键词 国家药品集中带量采购 抗菌药物 用药频度 限定日费用
暂未订购
基于真实世界数据的11个试点城市阿托伐他汀与瑞舒伐他汀国家集采政策效果评价——间断时间序列分析
16
作者 史锦仕 陈雯 +1 位作者 江滨 易湛苗 《中国医院药学杂志》 北大核心 2026年第2期159-166,共8页
目的:明确国家组织药品集中带量采购政策对11个试点城市阿托伐他汀、瑞舒伐他汀采购金额及用药频度的影响,科学评价该政策实施效果。方法:基于国家医保局集采数据系统,采用间断时间序列分析评估政策实施前后药品的月度采购金额和用药频... 目的:明确国家组织药品集中带量采购政策对11个试点城市阿托伐他汀、瑞舒伐他汀采购金额及用药频度的影响,科学评价该政策实施效果。方法:基于国家医保局集采数据系统,采用间断时间序列分析评估政策实施前后药品的月度采购金额和用药频度变化。结果:试点后,阿托伐他汀未中选原研药、中选仿制药、未中选过评仿制药的采购金额瞬时水平均显著下降(β_(2)=-14139.96,P<0.01;β_(2)=-2404.78,P=0.065;β_(2)=-1914.92,P<0.01)。对于用药频度,中选仿制药的瞬时水平显著上升(β_(2)=2403.21,P<0.01),且呈上升的变化趋势(β_(3)=76.96,P=0.119),原研药和未中选过评仿制药的瞬时水平均显著下降(β_(2)=-1847.91,P<0.01;β_(2)=-272.57,P<0.01)。瑞舒伐他汀的3类药品采购金额瞬时水平均显著下降(原研:β_(2)=-1120.27,P=0.012;中选仿制:β_(2)=-565.87,P=0.309;未中选过评仿制:β_(2)=-2049.11,P<0.01),中选仿制药用药频度瞬时水平显著上升(β_(2)=1132.83,P=0.004),原研药和未中选过评仿制药用药频度瞬时水平均显著下降(原研:β_(2)=-94.75,P=0.080;未中选过评仿制:β_(2)=-272.57,P<0.01)。结论:国家药品集采政策可优化他汀类药品采购结构,提升中选仿制药可及性,降低患者用药负担与医保支出,实现控费目标。 展开更多
关键词 集中采购 阿托伐他汀 瑞舒伐他汀 间断时间序列 政策效果
原文传递
基于质量功能展开方法优化医院集中带量采购药品管理服务
17
作者 郭晶晶 陈佩佩 +2 位作者 吴振波 张霞燕 骆松梅 《中国药物与临床》 2026年第1期37-42,共6页
目的 探讨将质量功能展开(QFD)方法应用于准确识别患者及医护人员对集中带量采购药品(简称集采药品)在药学服务中的需求,根据需求设计药学管理服务模式,优化药学服务,提升药学服务质量。方法 应用多维质量工具实施QFD,利用“质量屋”模... 目的 探讨将质量功能展开(QFD)方法应用于准确识别患者及医护人员对集中带量采购药品(简称集采药品)在药学服务中的需求,根据需求设计药学管理服务模式,优化药学服务,提升药学服务质量。方法 应用多维质量工具实施QFD,利用“质量屋”模式对集采药品的药学服务管理中的需求进行多层次分析,对改善前后的服务情况进行分析并评价。结果 经过活动实施,集采药品月度执行率改善至141.70%,目标达成率107.99%;集采中标药品使用比例改善至80.59%,目标达成率为104.41%;患者用药满意度改善至98.99%,达到目标值,并制定3项标准化作业书。结论 基于QFD的优化模型方法,以药学管理服务需求为中心,可以改进当前集采药品管理服务中存在的问题,把握管理服务的核心需求,构建集中药品管理服务新模式,提升药学服务质量。 展开更多
关键词 药品 质量功能展开模型 集中带量采购药品 管理服务
暂未订购
医院集采任务与药品储备智能化管理探索
18
作者 李雅琴 薛维佳 +3 位作者 潘智诚 黄蓉 蒙婷 金朝辉 《中国药业》 2026年第4期30-35,共6页
目的进一步加强医院集中带量采购(简称“集采”)药品的智能化管理水平。方法基于前期初探集采药品智能化监测系统经验,运用Power BI软件提供的桑基图、甘特图等数据可视化工具,扩展集采药品批次及目录管理功能,联合Python语言及其图形... 目的进一步加强医院集中带量采购(简称“集采”)药品的智能化管理水平。方法基于前期初探集采药品智能化监测系统经验,运用Power BI软件提供的桑基图、甘特图等数据可视化工具,扩展集采药品批次及目录管理功能,联合Python语言及其图形用户界面(GUI库)设计程序界面,创建集采任务项目管理窗口。结果与结论通过系统管理可快速调取所需报量药品目录,前瞻性地关注相关品种的集采信息及供应情况,为药品储备方案提供规范化、信息化支持,保障患者用药的同时,减少非中选药品库存堆积,也可为后续其他批次的集采报量工作提供参考。功能进一步完善后的集采药品智能监控系统,可更好地支持医疗机构适应提质扩面背景下集采药品的新需求。 展开更多
关键词 药品集中带量采购 提质扩面 智能化管理 数据可视化 PYTHON语言
暂未订购
基于DRG的集采伏立康唑片治疗真菌感染的临床研究
19
作者 李春芝 刘东 +4 位作者 彭善鑫 王玉玺 曹美琪 刘文启 任玉娇 《实用药物与临床》 2026年第1期11-15,共5页
目的比较集采伏立康唑片在呼吸内科某疾病诊断相关分组(Diagnosis-related group,DRG)病组的有效性、安全性和经济性。方法以临沂市人民医院为例,采用回顾性方法,收集2019年1月至2023年12月呼吸内科出院患者,遴选进入ES13病组并接受伏... 目的比较集采伏立康唑片在呼吸内科某疾病诊断相关分组(Diagnosis-related group,DRG)病组的有效性、安全性和经济性。方法以临沂市人民医院为例,采用回顾性方法,收集2019年1月至2023年12月呼吸内科出院患者,遴选进入ES13病组并接受伏立康唑片治疗的168例真菌感染患者的临床资料,按照治疗方案不同分为原研组(78例)和仿制组(90例)。以临床治疗有效率、住院天数和非计划重返再住院率评估治疗的有效性,以药物不良反应发生率评估安全性,以成本-效果比(Cost-effectiveness Ratio,CER)进行经济性评价。结果原研组和仿制组临床治疗有效率分别为89.74%和96.67%;住院天数为(7.26±3.30)d和(6.64±2.43)d;非计划重返再住院率为6.41%和5.56%;住院期间伏立康唑可能相关的丙氨酸转氨酶(ALT)升高发生率为2.56%和3.33%,差异均无统计学意义(P>0.05);仿制组的CER为35.66,原研组的CER为108.49,即使用仿制药进行治疗时,每获得1%有效率,成本可节约72.83元。结论仿制药伏立康唑片有效性和安全性不劣于原研药品,且更具成本-效果优势。 展开更多
关键词 伏立康唑 集中采购政策 疾病诊断相关分组 药物不良反应 成本-效果比
暂未订购
腔镜吻合器类耗材集中带量采购对胸部大手术的影响
20
作者 颜芬芬 王道雄 《中国医院建筑与装备》 2026年第2期8-12,共5页
基于真实世界数据,研究腔镜吻合器类耗材集中带量采购后的用量变化以及患者住院费用、治疗效果、治疗效率的变化情况。选取2022年7月—2023年6月以及2023年7月—2024年6月数据进行政策实施前后对比,采用独立样本t检验、Mann-Whitney U... 基于真实世界数据,研究腔镜吻合器类耗材集中带量采购后的用量变化以及患者住院费用、治疗效果、治疗效率的变化情况。选取2022年7月—2023年6月以及2023年7月—2024年6月数据进行政策实施前后对比,采用独立样本t检验、Mann-Whitney U检验等统计学方法对集中带量采购前后患者基本信息、住院总费用、各项费用、吻合器用量、治疗效果及效率等进行对比分析。研究结果表明,在集中带量采购后腔镜吻合器类耗材使用结构变化明显。该类耗材的集中带量采购,降低了除吻合器及钉仓之外的其他类耗材费用以及整体住院费用,有效促进了科室的业务水平发展,提高了医疗质量和医疗效率。 展开更多
关键词 腔镜吻合器类耗材 集中带量采购 胸部大手术
暂未订购
上一页 1 2 40 下一页 到第
使用帮助 返回顶部